Table 2.

Relationship of 2-week Ki67 and tumor shrinkage (single dimension RECIST) for IL1839/223 study, anastrozole only to 2 weeks ± gefitinib to 16 weeks, p for trend = 0.0504 and PALLET study (Letrozole only—group A), p for trend = 0.02.

Residual tum size % baseline	n	Ki67 > 10% n	Ki67 > 10% (%)
IL1839/223
>90	22	7	32
<90, ≥70	30	7	23
<70, ≥50	37	6	16
<50	14	1	7
PALLET study
≥90	22	8	36
<90 to ≥70	24	7	29
<70 to ≥50	20	3	15
<50	15	1	7